Integrating network pharmacology and experimental verification to investigate the pharmacological mechanisms of Buzhong Yiqi decoction in the treatment of non‐small cell lung cancer

Among all types of cancers, non‐small cell lung cancer (NSCLC) exhibits the highest mortality rate with a five‐year survival rate below 17% for patients. The Buzhong Yiqi decoction (BZYQD), traditional Chinese medicine (TCM) formula, has been reported to exhibit clinical efficacy in the treatment of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chemical biology & drug design 2024-01, Vol.103 (1), p.e14414-n/a
Hauptverfasser:	Zeng, Panke, Wang, Feng, Zhang, Jianing, ur Rashid, Haroon, Li, Xin, Zhang, Pengfei, Luo, Yunru, Wu, Xinyu
Format:	Artikel
Sprache:	eng
Schlagworte:	Buzhong Yiqi decoction Carcinoma, Non-Small-Cell Lung - drug therapy Drugs, Chinese Herbal - pharmacology experimental verification Humans Lung Neoplasms - drug therapy Molecular Docking Simulation Network Pharmacology non‐small cell lung cancer Phosphatidylinositol 3-Kinases PI3K‐AKT signaling pathway Proto-Oncogene Proteins c-akt
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!